Post Doctoral Fellow in Wellcome Trust DBT India Alliance project at NII, New Delhi

Applications are invited for the post of Post Doctoral Fellow for the following time-bound sponsored project as per the details given below:

Post : Post Doctoral Fellow

• Consolidated fellowship : As per terms governed by the Wellcome trust DBT India Alliance and National Institute of Immunology (a Minimum of Rs. 40,000/- per month). 
• Project title : Exploring the role of a developmental regulator in inflammatory immune response under Wellcome Trust DBT India Alliance

Essential Qualification : a. Must hold a Ph.D Degree (not awarded before 2009), or must already have submitted their thesis towards obtaining a Ph.D degree from a reputed Institute.
b. Must have more than Five years of research Experience.
c.  Must have proven research expertise/skills in basic biochemistry, cell biology and Molecular Biology, Research Expertise in in vivo animal work is also preferred.
d. Must have one publication as first author, in international journal, preferably with impact factor above 2.5.
e. Must have basic theoretical knowledge in the area such as cell signalling, inflammation, Immunology.

• Job description/Experience : The Candidate is ready to explore alteration in the host cell signalling and transcription network in response to pathogenic perturbations. The Candidate should have sound technical skills in cell culture and biochemistry and should have working theoretical knowledge in cell signalling. The candidate must have a Ph.D Degree (or must have submitted his/her thesis towards obtaining a Ph.D degree) and more than 5 years of experience in research laboratories. 

Duration : 30.11.2015
PI : Dr. Soumen Basak | sobasak@nii.ac.in  

How to Apply :Interested candidates may apply directly, STRICTLY IN THE PRESCRIBED FORMAT GIVEN ON WEBSITE through e-mail, to the Investigator of the project, clearly indicating the name of the project along with their complete C.V., e-mail id, fax numbers, telephone numbers. Short listed candidates will be required to submit attested copies of all their certificates and a Demand Draft of  Rs 100/- drawn on Canara Bank or Indian Bank payable at Delhi / New Delhi in favour of the Director, NII (SC / ST and PH candidates are exempted  subject to submission of documentary proof), at the time of interview.

Deadline : 28.03.12

http://202.54.226.233/announcement/AnnounceIndex_106.html

Indian researchers find the pathway to cancer

BANGALORE, Indian Researchers have achieved a breakthrough, identifying a protein pathway that triggers cancer in the human body owing to its erratic behaviour.

Researchers at Bangalore’s National Centre for Biological Sciences (NCBS) led by Satyajit Mayor and Neha Vyas have identified what is known as the Hedgehog pathway and the ways in which it forms and leads to cancer. The researchers, who have published their work in the journal, Cell, say this pathway is formed when the proteins (called hedgehog), which are separate, get drawn to each other by electrostatic interactions between amino acids present around the proteins.

A small cluster of proteins then gets formed and goes on to form a mega-cluster. This travels to other cells and creates effects that are good or bad — the cluster could be normal and help organ regeneration or tissue repair, or the cluster could get hyperactive and affect other cells, which is the sign that cancer is coming.

Simply put, the NCBS research indicates that hyperactivity of the hedgehog proteins within the human body can cause cancer and that its cluster formation has to be prevented to eliminate the possibility of hyperactivity entirely.

“Identifying the initial step that initiates the electrostatic attraction between amino acids that bring together hedgehog proteins in a cluster might help other scientists to design an anti-cancer drug that could stall a mutant hedgehog pathway in effective ways,” Said Neha. Such a drug could target the very source of these attractions — the amino acids that cause them — which are the first cause of cancer.

XTractor Premium - A Platform for discovery, analysis and modelling of published biomedical facts.

• The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis
  
• Innovative Features like Semantic Search, Concept Linking, Bibliographic search, Save, Export and Visualize
  
• Only Knowledgebase with daily updations from PubMed
  
• XTractor Premium now at Introductory Offer of $450 for Academic Researchers. Subscribe now and save $300!
  
• Register for WebEx
  
• Request for a Trial
  
  

Roche to Buy German Cell Analysis Company

Roche has reached an agreement with Innovatis to buy the cell analysis company for €15 million ($19.5 million), the Swiss life sciences firm said today. Roche said that the acquisition of the Bielefeld, Germany-based company, which focuses on automated cell analysis solutions including cell counting, viability testing, and cell function, fits with its strategy to strengthen its cell research market offerings.

Innovatis will become a fully integrated part of Roche Applied Science, and it will develop and market its products through that part of Roche's diagnostics division. Roceh said that Innovatis' technology will complement its existing cell analysis products and is synergistic with its xCelligence technology, which was launched last year.

"Roche has been one of our key customers for many years, in particular since the successful development of our cell analysis technology over 10 years ago," Innovatis CEO Michael Grohmann said in a statement. Roche said it expects the deal to close in a few weeks, after it receives approval from shareholders and is cleared by regulators.

Be part of XTractor community.

• XTractor the first of its kind - Literature alert service, provides manually curated & annotated sentences for the Keywords of your choice
  
• XTractor maps, extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies
  
• Enables customized report generation. With XTractor the sentences are categorized into biologically significant relationships
  
• The categorized sentences could then be tagged and shared across multiple users
  
• Provides users with the ability to create his own database for a set of Key terms
  
• Users could change the Keywords of preference from time to time, with changing research needs
  
• XTractor thus proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate
  
  

Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.

Invitrogen and Applied Biosystems to combine

Invitrogen Corporation and Applera Corporation today announced that their Boards of Directors have approved a definitive merger agreement, under which Invitrogen will acquire all of the outstanding shares of Applera's Applied Biosystems Group a cash and stock transaction valued at $6.7 billion.

This strategic combination will create a global leader in biotechnology reagents and systems generating approximately $3.5 billion in combined sales, with significant commercial, operational and technical scale, uniquely positioned to accelerate and drive new discoveries and commercial applications. The combined company will have a major presence in key growth markets and exceptional technical capabilities in the areas of genetic analysis, proteomics, cell biology and cell systems. Following the close of the transaction, the combined organization will be named Applied Biosystems, Inc. and will have its corporate headquarters in Carlsbad, California.

Under the terms of the merger agreement, Applera-Applied Biosystems shareholders will receive $38.00 for each share of Applera-Applied Biosystems stock they own in the form of Invitrogen common stock and cash. The expected split between cash and stock is 45% and 55%, respectively. Applera-Applied Biosystems shareholders will receive a value of $38.00 a share if the 20 day volume-weighted average price of Invitrogen common stock is in the range of $43.69 - $46.00 three business days prior to the close of the transaction. The total value per share will differ if Invitrogen's 20 day volume-weighted average price is above or below that range, measured shortly prior to the close of the transaction. The consideration represents a premium of 17% to Applied Biosystems's closing price on June 11, 2008, or 12% to Applied Biosystems's average closing price in the last 30 trading days. Applera-Applied Biosystems shareholders also will have the option to request all cash or all stock, subject to possible proration. Upon completion of the transaction, Invitrogen shareholders will own the majority of the company.

Do you want to know more?